An Open-Label, Multi-Center, Prospective Cross-Over Study of Preference and Safety of NovoFine® Autocover(TM) Needles Compared to BD Safety Glide (TM) Syringes in the Hospital Setting

Novo Nordisk A/S2 sites in 1 country83 target enrollmentStarted: July 2005Last updated: October 18, 2016

Conditions

Trial Snapshot

Phase: Phase 4
Status: Completed
Sponsor: Novo Nordisk A/S
Enrollment: 83
Locations: 2

Study Overview Study Design Eligibility Criteria Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to examine whether nurses prefer to use the NovoFine® Autocover Needle or the BD Safety Glide (TM) Syringe (only) in a hospital setting. The number of needle stick injuries will also be evaluated and whether these hospital nurses prefer the safety features of the NovoFine® Autocover Needle versus those of the BD Safety Glide (TM) Syringe. The identified hospital nurses will evaluate the two types of needles during standard administration of insulin to patients being treated for diabetes.

Study Design

Study Type: Interventional
Allocation: Randomized
Intervention Model: Crossover
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: Yes

Inclusion Criteria

•Hospital nurses with prior injection training without an infectious blood borne disease

Exclusion Criteria

Not provided

Investigators

Sponsor

Novo Nordisk A/S

Sponsor Class

Industry

Responsible Party

Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed

Phase 3

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in DiabeticsDelivery SystemsDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

NCT00773279Novo Nordisk A/S242

Completed

Phase 4

NovoLog Observation Trial in Subjects With Type 1 and Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1

NCT00095446Novo Nordisk A/S513

Completed

Phase 3

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2

NCT00097279Novo Nordisk A/S230

Completed

Phase 3

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2

NCT01527539Novo Nordisk A/S25

Completed

Phase 4

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCongenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors

NCT01561391Novo Nordisk A/S36